Publications by authors named "C Coutant"
Despite early diagnosis, approximately 20% of patients with ER-positive and HER2-negative breast cancer (BC) will experience disease recurrence. Improved survival has been reported with adjuvant treatment combining cyclin-dependent kinase 4/6 inhibitors with endocrine therapy, in high-risk patients with ER-positive and HER2-negative BC, regardless of age. Older patients have higher rates of ER-positive/HER2-negative BC than younger patients.
View Article and Find Full Text PDFReal-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.
Breast
December 2024
Article Synopsis
- The OlympiA study approved olaparib as an adjuvant treatment for high-risk early breast cancer patients with BRCA1/2 mutations, but the actual percentage of patients meeting these high-risk criteria in practical settings is unknown.
- The study analyzed data from the Côte d'Or Breast and Gynecological Cancer Registry, examining the long-term prognosis of patients treated for early breast cancer between 2005 and 2015, finding only 1.8% had BRCA mutations and 14.2% were classified as high risk.
- Results showed high-risk patients had significantly worse 10-year overall survival rates compared to other patients, highlighting the need for careful patient identification to ensure those who could benefit from olaparib receive appropriate care
Background: In immediate breast reconstruction (IBR), it is unclear whether there is any difference in the complication rates between prepectoral versus subpectoral implant placement without acellular dermal matrix (ADM).
Aim: To compare the rates of early post-operative complications and time to initiation of adjuvant treatment in patients undergoing IBR between prepectoral and subpectoral implant placement without ADM for the two surgical procedure.
Methods: We retrospectively retrieved data of patients who underwent IBR with prepectoral versus subpectoral implant placement between January 1, 2020 and December 31, 2022 in a large cancer center in France.
Background: The aim of this study is to investigate the added value of combining tumour blood flow (BF) and metabolism parameters, including texture features, with clinical parameters to predict, at baseline, the pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with newly diagnosed breast cancer (BC).
Methods: One hundred and twenty-eight BC patients underwent a F-FDG PET/CT before any treatment. Tumour BF and metabolism parameters were extracted from first-pass dynamic and delayed PET images, respectively.
Purpose: Postdiagnosis exercise is associated with lower breast cancer (BC) mortality but its link with risk of recurrence is less clear. We investigated the impact and dose-response relationship of exercise and recurrence in patients with primary BC.
Methods: Multicenter prospective cohort analysis among 10,359 patients with primary BC from 26 centers in France between 2012 and 2018 enrolled in the CANcer TOxicities study, with follow-up through October 2021.